861901-19-1

Usage

Ester form

Derived from 2-(2-fluoro-phenyl)-2-methylpropionic acid 2-(2-Fluoro-phenyl)-2-Methylpropionic acid Methyl ester is an ester, which means it is formed by the reaction of the corresponding carboxylic acid (2-(2-fluoro-phenyl)-2-methylpropionic acid) with an alcohol (methanol in this case).

Uses

Intermediate in synthesis of pharmaceuticals, agrochemicals, and other organic compounds This chemical is often used as a starting material or building block in the production of various drugs, pesticides, and other organic compounds.

Physical appearance

Colorless liquid The compound is a colorless liquid, which means it does not have any visible color when observed in its pure form.

Odor

Fruity The compound has a fruity smell, which may be reminiscent of various types of fruits.

Solubility

Soluble in organic solvents such as ethanol and ether 2-(2-Fluoro-phenyl)-2-Methylpropionic acid Methyl ester can dissolve in certain organic solvents, making it suitable for use in various chemical reactions and processes.

Hazards

Potential hazards to human health and the environment Due to its chemical nature, 2-(2-Fluoro-phenyl)-2-Methylpropionic acid Methyl ester may pose risks to both human health and the environment. It is important to follow proper safety precautions and disposal methods when handling 2-(2-Fluoro-phenyl)-2-Methylpropionic acid Methyl ester.

Upstream product

• 547-63-7 Methyl isobutyrate 
• 348-52-7 1-Fluoro-2-iodobenzene 
• 1072-85-1 o-fluorobromobenzene 
• 57486-67-6 methyl o-fluorophenylacetate 
• 74-88-4 methyl iodide 

Downstream Products

• 870849-49-3 2-methyl-2-(2-fluorophenyl)propanoic acid 
• 1035261-50-7 diethyl 2-(2-(2-fluorophenyl)-2-methylpropanoyl)malonate 
• 1017435-47-0 C₁₀H₁₀ClFO 

Relevant academic research and scientific papers

ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES

Aryl-substituted acetamide and pyrrolidin-2-one (γ-butyrolactam) derivatives have useful activity in the inhibition, prevention, or treatment of seizures. The derivatives may be useful in the treatment of epilepsy, including medically refractory epilepsy, and nerve agent poisoning.

HETEROCYCLIC COMPOUNDS

The present invention relates to compounds of the general formula (1) wherein the variables are defined as given in the description and claims. The invention further relates to uses of and to, processes and intermediates related to compounds of the general formula (I), wherein Q is wherein the substituents of I, Ia and Ib are as defined in description and claims.

α-Arylation of Esters and Ketones Enabled by a Bench-Stable Pd(I) Dimer Catalyst

A procedure for the α-arylation of α,α-disubstituted esters and ketones to generate quaternary carbon centers is described. The developed protocol is operationally simple and employs an air- and moisture-stable dinuclear Pd(I) complex [Pd(μ-I)(P t -Bu 3)] 2 to mediate selective α-arylation of aromatic C-I/Br bonds in the presence of aromatic C-Cl and/or C-OTf sites.

On the mechanism of the palladium-catalyzed β-arylation of ester enolates

The palladium-catalyzed β-arylation of ester enolates with aryl bromides was studied both experimentally and computationally. First, the effect of the ligand on the selectivity of the α/β-arylation reactions of ortho- and meta-fluorobromobenzene was described. Selective β-arylation was observed for the reaction of o-fluorobromobenzene with a range of biarylphosphine ligands, whereas α-arylation was predominantly observed with m-fluorobromobenzene for all ligands except DavePhos, which gave an approximate 1:1 mixture of α-/β-arylated products. Next, the effect of the substitution pattern of the aryl bromide reactant was studied with DavePhos as the ligand. We showed that electronic factors played a major role in the α/β-arylation selectivity, with electron-withdrawing substituents favoring β-arylation. Kinetic and deuterium-labeling experiments suggested that the rate-limiting step of β-arylation with DavePhos as the ligand was the palladium-enolate-to-homoenolate isomerization, which occurs by a β-H-elimination, olefin-rotation, and olefin-insertion sequence. A dimeric oxidative-addition complex, which was shown to be catalytically competent, was isolated and structurally characterized. A common mechanism for α- and β-arylation was described by DFT calculations. With DavePhos as the ligand, the pathway leading to β-arylation was kinetically favored over the pathway leading to α-arylation, with the palladium-enolate-to-homoenolate isomerization being the rate-limiting step of the β-arylation pathway and the transition state for olefin insertion its highest point. The nature of the rate-limiting step changed with PCy3 and PtBu3 ligands, and with the latter, α-arylation became kinetically favored. The trend in selectivity observed experimentally with differently substituted aryl bromides agreed well with that observed from the calculations. The presence of electron-withdrawing groups on these bromides mainly affected the α-arylation pathway by disfavoring C-C reductive elimination. The higher activity of the ligands of the biaryldialkylphosphine ligands compared to their corresponding trialkylphosphines could be attributed to stabilizing interactions between the biaryl backbone of the ligands and the metal center, thereby preventing deactivation of the β-arylation pathway.

NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF

Compounds of Formula (I) and Formula (II) are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula(I) and Formula (II) have the following structures, where the definitions of the variables are provided herein.

DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS

The application relates to novel amino alcohols of the general formula (I) where R, R1, R2, R3,R4, R5 and R6 each have the definitions illustrated in detail in the description, to a process for their preparation, and to the use of these compounds as medicines, in particular as renin inhibitors.